The addition of dipeptidyl peptidase-@ inhibitor therapy with sitagliptin to the treatment regime of patients with type @ diabetes mellitus and coronary artery disease is associated with a sustained improvement in myocardial performance during dobutamine stress and a reduction in postischemic stunning .